Ulta Beauty Inc. (NASDAQ:ULTA) is benefiting from the booming popularity of GLP-1 weight loss drugs, as users turn to hair and skincare products to address side effects like hair thinning and changes in skin elasticity.
GLP-1 Drugs Drive Beauty Product Demand
GLP-1 medications such as Ozempic and Wegovy have surged in use across the U.S., with roughly 10% of Americans reportedly on some form of weight-loss drug in 2025.
On Monday, Ulta CEO Kecia Steelman told Yahoo Finance’s Opening Bid that the trend is driving demand for beauty products.
“Hair loss with GLP-1s is real and products that can help with that,” Steelman said.
She added, “And then also skin elasticity, when you’re losing weight really rapidly. The skin elasticity is something that you’ve got to get moisture into.”
She noted a crossover …
This post was originally published here
